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ABSTRACT (246 words) 
Recent studies have shown that cancer risk related to overweight and obesity is mediated by time and 
might be better approximated by using life years lived with excess weight. In this study we aimed to 
assess the impact of overweight duration and intensity in older adults on the risk of developing different 
forms of cancer. Study participants from seven European and one US cohort study with two or more 
weight assessments during follow-up were included (n=329,576). Trajectories of body mass index (BMI) 
across ages were estimated using a quadratic growth model; overweight duration (BMI≥25) and 
cumulative weighted overweight years were calculated. In multivariate Cox models and random effects 
analyses, a longer duration of overweight was significantly associated with the incidence of obesity-
related cancer (overall Hazard Ratio (HR) per 10-yr increment: 1.36; 95%CI: 1.12-1.60), but also 
increased the risk of postmenopausal breast and colorectal cancer. Additionally accounting for the 
degree of overweight further increased the risk of obesity-related cancer. Risks associated with a longer 
overweight duration were higher in men than in women and were attenuated by smoking. For 
postmenopausal breast cancer, increased risks were confined to women who never used hormone 
therapy. Overall, 8.4% of all obesity-related cancers could be attributed to overweight at any age. These 
findings provide further insights into the role of overweight duration in the etiology of cancer and 
indicate that weight control is relevant at all ages. This knowledge is vital for the development of 
effective and targeted cancer prevention strategies.  
 
Keywords: CHANCES; Ageing; Cohort; Obesity; Cancer; Prevention 
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INTRODUCTION 
Obesity has emerged as one of the most prevalent risk factors for non-communicable diseases and is still 
on the rise in many populations.(1, 2) Currently about 69% of all US adults are considered overweight or 
obese (body mass index, BMI ≥25 kg/m2) and 35% obese (BMI ≥30 kg/m2), making it one of the countries 
with the highest prevalence of obesity in the world.(2, 3) Even though the level of obesity has been 
catching up in Western Europe over the past two decades, obesity prevalence is still presently lower 
than in North America, 20% in 2008.(4) In addition, overweight has become a growing problem 
specifically in the elderly, the fastest growing population segment in most high-income countries. For 
example, both in Europe and in the US, women aged 60 and above are more likely to be overweight or 
obese than any other age group. (3, 5)  
These developments have come at the cost of parallel rises in obesity-related morbidities, health care 
expenditures and mortality, most notably from cardio-vascular diseases and cancer.(6) In 2012, nearly 
half a million cancer cases globally were attributable to high BMI; more than half of this burden occurred 
in higher-income regions, most notably in Europe and Northern America.(7) These disparities across 
countries and regions not only reflect varying levels of obesity, but also differences in the strength of the 
cancer-obesity association between populations and in the prevalence and distribution of other risk 
factors modifying the association, such as smoking, diabetes and the use of hormone therapy (HT).(8, 9) 
Although the link between obesity and cancer is well-documented (8), most studies investigating this 
association are based on single measurements of height and weight at one point in life and evidence on 
the cumulative effects of overweight during the life course on disease risk remains scarce. Yet recent 
studies have shown that obesity duration is an important and independent predictor of type 2 diabetes 
(10), cardio-vascular disease (11) and all-cause mortality (12). Given that a longer exposure to 
overweight increases the risk and severity of insulin resistance, chronic inflammation, oxidative DNA 
damage and alterations in endogenous hormone levels (13) – all of which are thought to be cancer 
promotive – overweight duration may be an important, but also yet understudied, predictor of the risk 
of cancer development. 
In this study, we assessed the impact of overweight duration and intensity on cancer risk in more than 
300,000 older adults in a pooled dataset of seven European and one US prospective cohort studies. In 
secondary analyses, we evaluated the effects of important effect modifiers and confounders including 
sex, smoking status, diabetes and HT.  
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MATERIALS AND METHODS 
Study design and participants 
This study uses repeated anthropometric assessments obtained from seven European (EPIC Elderly 
Denmark, Greece, Netherlands, and Spain; ESTHER, Germany; PRIME Belfast, Northern Ireland; Tromsø, 
Norway) and one American cohort study (NIH AARP), pooled as part of the Consortium of Health and 
Aging: Network of Cohorts in Europe and the United States (CHANCES, www.chancesfp7.eu). A selection 
of the cohorts’ key characteristics is shown in Table 1. Additional information on the individual cohorts 
has been described elsewhere.(14) All CHANCES cohort studies are conducted in accordance with the 
Declaration of Helsinki. For each study, investigators satisfied the local requirements for ethical 
research, including obtaining informed consent from participants.  
Patients with a history of cancer at baseline (n=11,710)  or an unknown study exit (n=418) were 
excluded. Furthermore, for inclusion in this study, participants were required to have at least two valid 
BMI assessments during follow-up, including baseline and excluding assessments after or in the year 
preceding cancer diagnosis. For NIH AARP, participants with a retrospective self-reported BMI at age 50 
and height and weight assessments at baseline were included. Missing data on either smoking or 
physical activity status at baseline were excluded (n=16,398)). The derivation of the final number of 
included persons by study is portrayed in Figure 1.   
Outcomes 
Incident cancer cases were identified through linkage to cancer registries (EPIC NL, EPIC DK, NIH AARP, 
Tromsø) or through self-reports that were confirmed by medical records and/or pathology reports 
(ESTHER, PRIME Belfast) or both (EPIC Spain, EPIC Greece). Analyses were conducted for cancer sites 
where convincing evidence of a positive association with excess BMI was reported.(8, 15) We examined 
invasive breast cancer (ICD-O-3 C50) at postmenopausal ages, colorectal cancer (C18-21), as well as a 
combined obesity-related cancer category that also included cancer of the lower oesophagus (C15.5, as 
a proxy for oesophageal adenocarcinoma in the absence of histological data), gastric cardia (C16.0), liver 
(C22), gallbladder (C23), pancreas (C25), , endometrium (C54), ovary (C56) and kidney (C64)   
Exposure variables 
Overweight was defined as having a BMI above 25 kg/m2. BMI values below 15 kg/m2 and above 45 
kg/m2 were considered highly unlikely and hence considered as missing.  For all European studies except 
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ESTHER, where only self-reported anthropometry was available, BMI at baseline was calculated based 
on measured height and weight. At re-contact, data on height and weight were self-reported in all 
cohorts, except PRIME Belfast and Tromsø where BMI at follow-up was based on measured 
anthropometry. In NIH AARP, height and weight were self-reported at age 50 (retrospectively) and at 
baseline. Supplementary Figure 1 provides an overview of the study-specific timing of repeated 
anthropometric measurements by cohort. 
Covariates 
Baseline information on all covariates except alcohol consumption (continuous, grams/day) were 
available as categorical variables as follows: (daily) smoking status (never smoker/former 
smoker/current smoker), vigorous physical activity (yes/no, for performing intense exercise at least once 
a week), highest level of education (primary or less/more than primary but less than college or 
university/college or university), HT use (never/ever). Other information on reproductive history and 
diet were not consistently available in all cohorts and could not be taken into account in our analyses.  
Statistical analysis 
The analysis was carried out in three steps. First, a quadratic growth model with a random intercept and 
random slope was used to predict individual BMI trajectories for each study participant.(16, 17) This 
model was developed and adjusted in a step-wise manner by adding study, sex, smoking status, physical 
activity and an interaction term for study and contact age to the fixed effects part of the model. The 
obtained predicted BMI values for all ages between study entry (baseline) and study exit were then used 
to estimate overweight (BMI≥25) duration in years. Weighted cumulative overweight years (OWY) were 
computed by multiplying the duration of overweight in years by the difference (in BMI units) above 
normal BMI (BMI≥25) for each increment of age. This measure takes into account the degree of 
overweight over time and is comparable to pack-years in relation to tobacco smoking. For example, 
when considering 10 years of follow-up, a person with BMI=26 would accumulate 10 OWY (26-25*10) 
and 10 years of overweight duration; a person with a BMI=35 would accumulate 100 OWY (35-25*10). 
Overweight duration was assessed per 10-year increment and cumulative OWY per 100 units.  
Secondly, Cox proportional hazard models with age as time metric were used to estimate hazard ratios 
(HR) and 95% confidence limits (CI) to describe the relation between overweight duration, cumulative 
OWY and the risk of developing cancer. Overweight duration and cumulative OWY were treated as 
continuous, time-dependent covariates in the model. Baseline information was used for all other 
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covariates. Subjects were censored at death, lost to follow-up (i.e. emigration, opt-out), any cancer 
excluding non-melanoma skin cancer (C44) diagnosis other than the site of interest or cohort-specific 
end-of-follow up, whichever occurred first. For all outcomes, three models with different sets of 
adjustments were fitted. In model 1, adjustments were made for sex. Model 2 was additionally adjusted 
for smoking status and physical activity. In model 3, further adjustments were made for education and 
alcohol consumption. The proportional hazard assumptions were assessed by visual inspection of log-log 
plots and by statistical tests using Schoenfeld residuals. Any covariates for which proportional hazards 
were unlikely were stratified, but the final results were not materially different from the unstratified 
models.   
 
All analyses were carried out for each study separately and the results were then combined using 
random-effects meta-analysis in order to limit the influence of study size (especially with regard to the 
NIH AARP cohort). (18) Data from all cohorts were then pooled to describe the dose-response 
relationship between overweight duration, intensity and cancer risk and to assess interactions in 
stratified analyses by sex, smoking status, HT use and diabetes history. We used restricted cubic splines 
with four knots at Harrell’s default percentiles to model non-linear relations between obesity duration, 
OWY and cancer risk. Analyses of the pooled data were additionally adjusted for study. 
 
Lastly, and based on the assumption that the association between overweight and the cancer sites 
included in our study is causal (19), population attributable fractions (PAF) and their 95% CIs were 
calculated (20, 21) using the maximum likelihood method (22) and the ‘punaf’ command in Stata. PAFs 
represent the proportion of obesity-related cancer cases that could have been avoided if participants 
were never overweight during follow-up.  
All statistical analyses were performed using Stata 12. 
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RESULTS 
In total, 329 576 participants were included in this study, with 16 520 obesity-related cancer cases 
occurring during follow-up (Table 1). Study participants were recruited between 1991 and 2003, with a 
mean age at study entry ranging from 54 years in Northern Ireland (PRIME Belfast) cohort to 67 years in 
Greece (EPIC elderly). Education level (highest attained degree) was particularly high in the US (NIH 
AARP) (75% with college or university degree), while more than 85% of the Spanish participants (EPIC 
elderly) had only primary education or less. Mean BMI at baseline ranged between 25.8 kg/m2 in the 
Netherlands to 29.5 kg/m2 in Spain, where 42% of the study participants were classified as obese 
(BMI≥30). While 75% of all participants from Denmark (EPIC elderly) reported to be physically active, 
this applied to only 5% in Spain. Alcohol intake was highest in Denmark (20.2 g/d) and lowest in Norway 
(Tromsø – 3.6 g/d), in contrast with smoking, where Norway had the highest and Greece the lowest 
proportion of current daily smokers (31% and 12% respectively). Median follow-up ranged between 10.4 
years in Germany (ESTHER) and 18.0 years in Northern Ireland (PRIME Belfast). Age-standardized 
incidence rates of obesity-related cancers ranged between 351 per 100 000 person-years in the US to 45 
per 100 000 in Greece.  
In the meta-analysis of all studies, a longer duration of overweight was significantly associated with an 
increased risk of obesity-related cancer combined (Hazard Ratio (HR) per 10-yr increment: 1.36; 95%CI: 
1.12 to 1.60) and was most pronounced in the German ESTHER cohort (HR: 2.29, 95%CI: 1.66 to 3.14), 
but not statistically significant in the Spanish and Danish EPIC cohorts and PRIME Belfast (Figure 2). 
When taking the degree of overweight over time into account, risks tended to be slightly more 
pronounced, especially in the US NIH AARP cohort (Figure 2), but also overall (HR per 100-unit 
increment in OWY: 1.46; 95%CI: 1.14 to 1.77). While results were similar for postmenopausal breast and 
colorectal cancer, higher risks were found for other obesity-related sites, comprising cancer of the 
pancreas, kidney, gallbladder and endometrium. HRs for the association between overweight duration 
and cumulative OWY by cancer site and cohort, for the different models are presented in 
Supplementary Table 1. As adjustments for alcohol consumption and education level in model 3 only 
marginally altered the results of model 2, the latter simpler model was used when exploring dose-
response relationships between increasing overweight duration, intensity and cancer risk. Clear 
associations were found for all obesity-related cancer sites combined, but also for breast cancer in HT 
non-users (Figure 3, panel A). When taking into account the degree of overweight over time, the risk 
increase became more pronounced, especially for other obesity-related cancers (Figure 3, panel B). This 
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relationship was mainly driven by kidney and endometrial cancer, showing exponential associations with 
the combination of overweight duration and intensity over time (data not shown). 
The population attributable fraction (PAF) for ever being overweight during follow-up was 8.4% (95%CI: 
6.3 to 10.5%) for obesity-related cancers combined (Table 2). PAFs were considerably higher in men 
than in women (20.0% vs 4.6%), in never smokers relative to current and past smokers and in those with 
a history of diabetes type 2. In women who never used HT, 15.6% (11.8 to 19.2%) of all breast cancers 
were attributable to ever being overweight during follow-up.  
In secondary analyses, we investigated the potential confounding effects of sex, smoking status, HT use 
and diabetes history in the pooled dataset (Supplementary Table 2). Generally, the risks associated with 
both overweight duration and cumulative OWY were higher in men than in women. After stratification 
for sex, the risk of colorectal cancer associated with a longer overweight duration and intensity (OWY) 
reached statistical significance in both men and women. Gradients in risk were found across smoking 
categories, indicating that the risk of obesity-related cancer due to overweight duration and/or 
cumulative OWY was highest among never smokers, intermediate among former smokers and low or 
negligible in current smokers. For breast cancer, significantly increased risks were observed in women 
who never used HT, with similar effect sizes for both overweight duration (HR: 1.41, 95%CI: 1.25 to 1.58) 
and cumulative OWY (HR: 1.33, 95%CI: 1.15 to 1.53). Risks of obesity-related cancers were higher in 
study participants who ever reported type 2 diabetes relative to those who had no diabetes history, 
especially when the degree of overweight over time was taken into account. 
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DISCUSSION 
Based on a pooling of eight cohort studies, 300 000 participants and more than 16 000 obesity-related 
cancers, this is the first study to assess the impact of overweight duration on cancer risk in older 
populations. Overall, we found that a longer duration of overweight was significantly associated with a 
higher risk of postmenopausal breast and colorectal cancer, as well as for obesity-related cancers 
combined. Risks associated with a longer overweight duration were higher in men than in women and 
among non-smokers than in current smokers. For post-menopausal breast cancer, increased risks were 
confined to women who never used HT. When additionally taking the degree of overweight over time 
into account, risks increased even further. Overall, 8.4% of obesity-related cancers could be attributed 
to being overweight at any time point after age 50 (10.7% in never smokers).  
These findings are consistent with studies reporting associations between high BMI at one point in time 
and cancer risk (8, 23) and are in line with evidence on the impact of obesity duration on other health 
outcomes, including type 2 diabetes, cardiovascular disease and all-cause mortality.(10-12) One of the 
putative underlying biological mechanisms involves changes in the metabolism of sex-steroid hormones, 
namely oestrogen, which is mainly produced by fat tissue in postmenopausal women.(24) Hence, a 
longer overweight duration increases the exposure time to elevated hormone levels, which may in turn 
increase the risk of developing cancer. In our study, we found that the increased risk of postmenopausal 
breast cancer related to a longer overweight duration was confined to women who never used HT and 
risks were similar for overweight duration and OWY. This finding suggests that exogenous oestrogen and 
hormone levels modify the association between overweight duration and postmenopausal breast 
cancer, as noted in previous studies.(25, 26) While similar associations have also been reported for 
endometrial cancer (27, 28), evidence for effect modification for colorectal cancer is inconsistent across 
studies.(29, 30)  
We also noted important sex differences in the risk of developing obesity-related cancer associated with 
increasing overweight duration. Higher risks in men were mainly evident for colorectal cancer and all 
obesity-related cancers combined. This is consistent with previous studies pointing towards a stronger 
link between different measures of obesity and colorectal cancer in men, with the association much 
weaker or absent in women.(31, 32) Increased waist circumference has been suggested to be a better 
predictor of colorectal cancer risk than BMI that varies markedly by sex.(32, 33)  Waist circumference is 
a proxy for visceral adipose tissue, where leptin and adiponectin are predominantly secreted. 
Adiponectin is inversely correlated with body fatness, is anti-inflammatory and inhibits tumour growth 
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in animals.(34) As circulating levels of adiponectin have been found to be higher in women than men, 
this may offer an explanation for sex differences in colorectal cancer risk associated with overweight and 
obesity.(31) When assessing the dose-response relationship between overweight duration and cancer 
risk, we also noted that peaks in risk differed by cancer site, possibly reflecting early and late 
promotional effects of adiposity for some cancers. Yet, the site specific numbers of cases were too small 
to draw firm conclusion from this finding. 
Another important confounder was smoking. We found that the effect of increasing overweight 
duration on the risk of developing obesity-related cancer was stronger in never smokers relative to 
current smokers. This association was more pronounced when the degree of overweight was taken into 
account, and is supported by previous findings on the role of smoking in the obesity-cancer pathway. (8, 
35, 36) Other factors such as hormones and circulating levels of DNA adducts have been suggested to 
contribute to lower risks of obesity-related cancers observed in smokers. (8, 37-39) In contrast, history 
of type 2 diabetes modified the overweight-cancer association in our study in a way that participants 
with a positive history had the greatest risk. This finding confirms previous findings on the interaction 
between overweight duration, diabetes and pancreatic cancer.(40)    
While our findings were largely consistent across studies, we generally found weaker associations in the 
US cohort when compared to the European cohorts. The between-study heterogeneity could only 
marginally be reduced by accounting for sex, HRT use and smoking, suggesting that other (unmeasured) 
factors must be responsible for the differences observed across studies. At least in parts, this may also 
be explained by differences in the baseline characteristics between European and US study participants 
as well as the respective study sizes. In comparison with the combined European cohorts, comprising 38 
563 study participants, the US NIH AARP cohort was much larger (291 013 participants), and hence 
better powered. Additionally, the majority of the US NIH AARP participants were highly educated and 
less likely to be current smokers or physically inactive than participants of the European cohorts, limiting 
the generalizability of the findings to the general US population. Yet, given the similar associations found 
across the studies and the general notion that the effect of obesity on cancer development should not 
differ between Europeans and North Americans, we believe that our results are valid and most likely a 
conservative estimate of the true effect. 
In the pooled analysis, we were able to include a large number of study participants from several 
European countries and the US, which enabled an assessment of the dose-response relationship 
between overweight duration and cancer risk, as well as related sensitivity analyses. However, some 
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methodological considerations and limitations should be noted. In the first step of our analysis, we used 
repeated measurements and self-reports of height and weight to model BMI across ages using a growth 
curve model. With this approach, we were able to estimate each study participant’s BMI trajectory and 
overweight duration during follow-up. When put into context with the observed BMI, the trajectories 
predicted by the model were fitting well, also owing to the fact that in most individuals BMI typically 
changes only marginally during adulthood (and if so, only slowly).(41, 42) As the results from the 
German ESTHER study (where only self-reported height and weight were available) were consistent with 
those from the other European cohorts (where BMI was calculated based on measured height and 
weight), we believe that the type of BMI information has not unduly affected our overall findings. When 
we repeated the analyses with obesity (BMI≥30) duration, the associations became slightly stronger. 
Due to the fact that there were no anthropometric data available before baseline (except in NIH AARP), 
we could only evaluate overweight duration and intensity after study entry, i.e. in the elderly, and could 
not take into account overweight earlier in life. This might have led to the unexpected shape of the 
dose-response curves (Figure 3), especially in the first years. Even though our results may not reflect 
risks on the individual-level (owing to the observational study design), the dose-response curves indicate 
that risk may be better approximated by taking both overweight duration and intensity into account.  
It is furthermore important to note that BMI may not be an ideal measure of body fatness since it can 
reflect both adiposity and muscularity and is limited in its ability to predict body fatness across ethnic 
groups and age.(43) Age-related decreases in height might falsely lead to an increase in BMI and with 
advancing age fat tissue tends to be redistributed towards the abdominal region.(43) Hence, it might 
have been more appropriate to use one of the measures of central obesity as a surrogate for overweight 
and obesity as these have been suggested to better predict obesity-related health outcomes when 
compared to BMI.(44, 45) These measures were however not available longitudinally from the cohorts 
included in this study. Yet, in a companion paper using data from the same cohorts (except NIH-AARP), 
we found that the risk associated with a standard deviation increase in baseline BMI and waist 
circumference were similar for post-menopausal breast, colorectal and obesity-related cancers 
combined (Heinz Freisling, personal communication).  
Further limitations of our study are related to differences in study design between cohorts, including 
differences in length of follow-up, anthropometric assessment methods and their frequency, as well as 
the comparability of several variables. In order to harmonize the data and variable definitions across 
cohorts, some variables such as physical activity were only available in binary form (yes/no). Despite 
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adjustment for the main confounding factors, namely smoking and physical activity, we cannot rule out 
confounding by other unmeasured factors, most importantly reproductive risk factors and diet. As these 
were not consistently available from all cohorts, we were not able to take these into account in our 
analyses.  
Lastly, it is important to acknowledge a number of methodological limitations, which we hope will 
prompt further research. In the same way that we have estimated cumulative exposure for our main 
independent variable, overweight duration, it may be surmised that the nature of the confounding or 
moderating effects of other exposures (such as smoking, alcohol intake or physical activity) might, in 
uncertain ways, depend on how their own cumulative effects have been modelled. Related to this is the 
fact that methodologists have recently debated about the correct way to model cumulative effects, 
when their effects on absolute rather than relative risk scales might differ and when more complex 
temporal patterns of exposure may not be modelled well on a proportional hazards scale. (46-48) 
 
Implications and conclusions 
We report that longer overweight duration increases the risk of cancer in older adults, in both Europe 
and the US, with 8.4% of obesity-related cancers attributable to overweight at any time point after age 
50. Each of the studies included in this analysis was based on a prospective design, with data collection 
prior to disease onset. Thus, a degree of causality between overweight duration and cancer 
development can be inferred, although with great caution. These observations lend further credibility to 
existing clinical recommendations for weight reduction in the obese and the maintenance of healthy 
weight in the non-obese, irrespective of age. Avoidance of weight gain, engaging in physical activity, and 
even small amounts of weight loss have been suggested to prevent adverse health consequences of 
obesity in the elderly.(43, 49) Future studies should further investigate the specific roles of age at onset 
of overweight and different BMI trajectories on cancer risk. 
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FIGURE LEGENDS 
 
Fig 1 Flowchart of participant inclusion 
 
Fig 2 Hazard ratios (HR)* and their 95% confidence intervals (95% CI) for overweight (BMI≥25) duration 
and weighted cumulative overweight years (OWY), by cohort and cancer site, men and women 
combined. 
* results from random-effects meta-analysis with adjustments for sex, smoking status, physical activity (yes/no), alcohol consumption and 
education level (Model 3) 
a breast, colorectum, pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
b pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
 
 
Fig 3 Hazard ratios (HR) and their 95% confidence intervals (95%CI) for the association between (A) 
overweight (BMI≥25) duration, (B) weighted cumulative overweight years (OWY) and cancer risk, men 
and women combined 
a breast, colorectum, pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
b pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
The figure shows a 3-knot spline of the relation between overweight duration and cancer risk, allowing for non-linear effects and adjusted for 
sex, study, smoking status and physical activity (Model 2). Restricted cubic splines very fitted with knots at 0, 1, 5 and 10 years for overweight 
duration and at 0, 1, 13 and 65 for OWY. P-values are for non-linearity.  
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Table 1. Selected cohort characteristics 
                
 
EPIC-Elderly Germany 
(ESTHER) 
Northern 
Ireland (PRIME 
Belfast) 
Norway 
(Tromsø) 
USA                
(NIH AARP) 
 
Denmark Greece Netherlands Spain 
Baseline characteristics (n=6,871) (n=6,877) (n=4,149) (n=4,550) (n=8347) (n=1,920) (n=5,849) (n=291,013) 
         
Recruitment year (range) 1993-1997 1994-1999 1993-1997 1992-1996 2000-2003 1991-1994 1994-1995 1995-1997 
Mean age, in years (SD) 62.5 1.5 67.0 4.4 64.3 2.8 62.5 1.7 61.8 6.6 54.2 2.8 59.4 6.9 62.2 5.3 
Sex  
                   Men 3521 51.2% 2693 39.2% 154 3.7% 1931 42.4% 3784 45.3% 1920 100.0% 2736 46.8% 173053 59.5% 
   Women 3350 48.8% 4184 60.8% 3995 96.3% 2619 57.6% 4563 54.7% 0 0.0% 3113 53.2% 117960 40.5% 
Education 
                   Low (primary or less) 2451 35.7% 6281 91.3% 1279 30.8% 3899 85.7% 6025 72.2% 15 0.8% 2999 51.3% 1391 0.5% 
   Medium (more than primary but less than college) 3040 44.2% 379 5.5% 2364 57.0% 317 7.0% 1736 20.8% 1655 86.2% 1710 29.2% 64968 22.3% 
   High (college or university) 1366 19.9% 200 2.9% 503 12.1% 284 6.2% 412 4.9% 250 13.0% 1108 18.9% 218567 75.1% 
   Missing 14 0.2% 17 0.2% 3 0.1% 50 1.1% 174 2.1% 0 0.0% 32 0.5% 6087 2.1% 
Mean BMI at baseline (SD) 26.1 3.8 29.3 4.3 25.8 3.9 29.5 4.0 27.6 4.2 26.1 3.2 26.1 3.7 26.8 4.5 
   Underweight (BMI < 18.5) 35 0.5% 18 0.3% 45 1.1% 4 0.1% 33 0.4% 8 0.4% 43 0.7% 2448 0.8% 
   Normal weight (BMI ≥ 18.5 & BMI < 25) 2819 41.0% 1062 15.4% 1891 45.6% 491 10.8% 2268 27.2% 717 37.3% 2352 40.2% 105194 36.1% 
   Overweight (BMI ≥ 25 & BMI < 30) 3096 45.1% 2997 43.6% 1674 40.3% 2151 47.3% 3953 47.4% 980 51.0% 2634 45.0% 123544 42.5% 
   Obese (BMI ≥ 30) 921 13.4% 2800 40.7% 539 13.0% 1904 41.8% 2093 25.1% 215 11.2% 820 14.0% 59827 20.6% 
Vigorous physical activitya 
                   No 1742 25.4% 5418 78.8% 1669 40.2% 4308 94.7% 4678 56.0% 1668 86.9% 3526 60.3% 150872 51.8% 
   Yes 5129 74.6% 1459 21.2% 2480 59.8% 242 5.3% 3669 44.0% 252 13.1% 2323 39.7% 140141 48.2% 
Alcohol intake  
(average daily consumption in grams) 20.2 
 
7.4 
 
7.8 
 
13.0 
 
6.8 
 
20 
 
3.6 
 
13.3 
    N missing 0 0.0% 0 0.0% 0 0.0% 0 0.0% 664 8.0% 0 0.0% 1082 18.5% 0 0.0%
Smoking statusa 
                   Never daily smoker 2293 33.4% 4830 70.2% 2002 48.3% 3095 68.0% 4188 50.2% 792 41.3% 1935 33.1% 106549 36.6% 
   Former daily smoker 2650 38.6% 1257 18.3% 1482 35.7% 722 15.9% 2771 33.2% 637 33.2% 2107 36.0% 151248 52.0% 
   Current daily smoker 1928 28.1% 790 11.5% 665 16.0% 733 16.1% 1388 16.6% 491 25.6% 1807 30.9% 33216 11.4% 
Hormone therapy useb 
                   Ever 1686 50.3% 0 0.0% 3299 82.6% 2310 88.2% 1965 43.1% n/a 1475 47.4% 52021 44.1% 
   Never 1564 46.7% 0 0.0% 692 17.3% 288 11.0% 2287 50.1% n/a 873 28.0% 65939 55.9% 
   Missing 100 3.0% 4184 100.0% 4 0.1% 21 0.8% 311 6.8% n/a 765 24.6% 0 0.0% 
Self-reported or documented diabetes type 2 
                   No 6429 93.6% 5924 86.1% 3986 96.1% 4026 88.5% n/a n/a n/a 266601 91.6% 
   Yes 143 2.1% 944 13.7% 159 3.8% 515 11.3% n/a n/a n/a 24412 8.4% 
   Missing 299 4.4% 9 0.1% 4 0.1% 9 0.2% n/a n/a n/a 0 0.0% 
Median follow-up time (years) 11.9 11.5 13.2 13.4 10.4 18.0 15.9 10.5 
N cancers cases (N/incidence ratec per 100 000) 734 
 
340 
 
403 
 
483 
 
845 
 
256 
 
722 
 
53094 
    N breast cancer (age>50, women only) 110 42.4 21 9.3 109 57.0 42 21.4 120 86.0 0 0.0 64 39.1 5903 152.9 
   N colorectal cancer 94 37.4 37 10.1 77 39.3 66 35.1 110 67.8 40 75.3 112 53.9 4469 93.5 
   N other obesity-relatedd 76 30.3 65 25.4 56 27.5 56 28.1 113 70.2 15 29.3 64 34.3 4701 104.7 
   N obesity-relatede 280 110.0 123 44.7 242 123.7 164 84.6 343 224.0 55 104.6 240 127.4 15073 351.1 
                                  
a participants with missing information on physical activity and smoking status were excluded;  b women only 
           c age-standardized to the World standard population;  d pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
e other obesity-related sites plus breast and colorectal cancer 
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Table 2. Population attributable fractions (PAF) of ever being overweight (body mass index ≥ 25kg/m2)  and cancer risk 
  
Obesity-related 
cancersa Breast cancer Colorectal cancer 
Other obesity-related  
cancersb 
 
% ever 
overweight PAF (95% CI) PAF (95% CI) PAF (95% CI) PAF (95% CI) 
  
 
                
Overall 68.6% 8.4% (6.3-10.5) 
  
9.6% (5.3-13.8) 19.4% (15.5-23.1) 
   Men 75.0% 20.0% (15.7-24.0) 
  
13.3% (7.3-18.9) 28.2% (22.1-33.9) 
   Women 60.0% 4.6% (2.2-6.9) * * * * 13.0% (8.1-17.6) 
   Current daily smoker 59.1% * * * * * * 9.9% (0.5-18.4) 
   Former daily smoker 72.2% 8.8% (5.5-12.0) * * 8.7% (2.2-14.8) 22.1% (16.2-27.6) 
   Never daily smoker 67.1% 10.1% (6.7-13.4) * * 15.2% (8.0-21.8) 19.7% (13.4-25.6) 
   Diabetes ever 85.8% 17.5% (5.0-28.3) * * * * 42.1% (24.1-55.9) 
   Diabetes never 66.7% 6.9% (4.7-9.1) * * 8.6% (4.0-13.0) 16.3% (12.2-20.2) 
   HRT ever users 54.7% * * * * * * * * 
   HRT never users 63.7% 15.6% (11.8-19.2) 17.9% (12.6-22.8) * * 23.3% (16.1-29.8) 
 
a breast, colorectum, pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
b pancreas, kidney, gallbladder, endometrium, ovary, liver, lower oesophagus, cardia stomach 
* PAF not calculated because HR statistically non-significant. 
 
 
